Iron and Micronutrient Deficiencies as Drivers of Carcinogenesis and Therapeutic Resistance in Cancer: An In-Depth Clinical and Physiological Three-Part Review - Part I—Iron Deficiency, Insufficiency, Excess, and Neoplasia
Main Article Content
Abstract
The 2019 Nobel Prize in Physiology or Medicine underscored a fundamental insight: cellular oxygen-sensing and hypoxia pathways orchestrate key biological responses, including the initiation and progression of cancer. Building on this framework, this review translates the core science of oxidative stress and hypoxia-driven molecular alterations into practical clinical strategies. Latent iron deficiency and iron overload are both common, frequently underdiagnosed, and potent mediators of redox activity capable of driving carcinogenesis.
This manuscript presents a mechanistic narrative review of how iron deficiency and iron overload generate reactive oxygen species (ROS), promote tumor initiation, progression, and resistance to therapy.
Emphasis is placed on equipping clinicians who manage patients with hereditary cancer predisposition, subclinical premalignant lesions, or early biomarkers of oncogenesis to recognize iron imbalance earlier and implement targeted surveillance and timely intervention before developing neoplastic lesions.
Article Details
How to Cite
TISMAN, Glenn.
Iron and Micronutrient Deficiencies as Drivers of Carcinogenesis and Therapeutic Resistance in Cancer: An In-Depth Clinical and Physiological Three-Part Review - Part I—Iron Deficiency, Insufficiency, Excess, and Neoplasia.
Medical Research Archives, [S.l.], v. 13, n. 12, jan. 2026.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/7182>. Date accessed: 02 jan. 2026.
doi: https://doi.org/10.18103/mra.v13i12.7182.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Herbert V. Everyone should be tested for iron disorders. J Am Diet Assoc. 1992;92(12):1502-1509.
2. Soppi ET. Iron deficiency without anemia. a clinical challenge. Clin Case Rep. 2018;6(6):1082–1086. doi:10.1002/ccr3.1529
3. Galaris, D., & Pantopoulos, K. (2008). Oxidative stress and iron homeostasis: Mechanistic and health implications. Critical Reviews in Clinical Laboratory Sciences, 45(1), 1–23. doi:10.1080/10408360701713104
4. Papanikolaou, G., & Pantopoulos, K. (2005). Iron metabolism and toxicity. Toxicology and Applied Pharmacology, 202(2), 199–211. doi:10.1016/j.taap.2004.06.021
5. Semenza, G. L. (2010). HIF-1: Upstream and downstream of cancer metabolism. Current Opinion in Genetics & Development, 20(1), 51–56. doi:10.1016/j.gde.2009.10.009
6. Pugh, C. J., & Ratcliffe, P. J. (2003). Regulation of angiogenesis by hypoxia: Role of the HIF system. Nature Medicine, 9(6), 677–684. doi:10.1038/nm0603-677
7. Denko, N. C. (2008). Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature Reviews Cancer, 8(9), 705–713. doi:10.1038/nrc2468
8. Mimura, I., & Tanaka, T. (2015). Hypoxia-inducible factors as molecular targets for cancer stem cells. Cancer Science, 106(6), 665–671. doi:10.1111/cas.12664
9. Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014). PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. Journal of Experimental Medicine, 211(5), 781–790. doi:10.1084/jem.20131916
10. Qian, Y., Chen, X., & Liu, X. (2020). PD-L1 expression in solid tumors: The role of hypoxia and its clinical implications. Frontiers in Immunology, 11, 582555. doi:10.3389/fimmu.2020.582555
11. Rankin, E. B., & Giaccia, A. J. (2016). Hypoxic control of metastasis. Science, 352(6283), 175–180. doi:10.1126/science.aaf4405
12. Wigerup, C., Påhlman, S., & Bexell, D. (2016). Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacology & Therapeutics, 164, 152–169. doi:10.1016/j.pharmthera.2016.04.009
13. Ward PA, Lentsch AB. The acute inflammatory response and its regulation. Arch Surg. 1999;134(6):666–669. doi:10.1001/archsurg.134.6.666
14. Karin, M., & Greten, F. R. (2005). NF-κB: Linking inflammation and immunity to cancer development and progression. Nature Reviews Immunology, 5(10), 749–759. doi:10.1038/nri1703
15. Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004). NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature, 431(7007), 461–466. doi:10.1038/nature02924
16. Kerins, M. J., & Ooi, A. (2018). The roles of NRF2 in modulating cellular iron homeostasis. Antioxidants & Redox Signaling, 29(17), 1756–1773. doi:10.1089/ars.2017.7177
17. Toyokuni, S., Ito, F., Yamashita, K., Okazaki, Y., & Akatsuka, S. (2020). Iron overload and its impact on redox signaling in carcinogenesis. Free Radical Biology and Medicine, 159, 82–94. doi:10.1016/j.freeradbiomed.2020.07.019
18. Hayes, J. D., Dinkova-Kostova, A. T., & Tew, K. D. (2020). Oxidative stress in cancer. Cancer Cell, 38(2), 167–197. doi:10.1016/j.ccell.2020.06.001
19. Morgan, M. J., & Liu, Z. G. (2011). Crosstalk of reactive oxygen species and NF-κB signaling. Cell Research, 21(1), 103–115. doi:10.1038/cr.2010.178
20. Rojo de la Vega, M., Chapman, E., & Zhang, D. D. (2018). NRF2 and the hallmarks of cancer. Cancer Cell, 34(1), 21–43. doi:10.1016/j.ccell.2018.03.022
21. Tafani, M., Sansone, L., Limana, F., Arcangeli, T., De Santis, E., Polese, M., Fini, M., & Russo, M. A. (2016). Hypoxia increases the resistance of tumors to therapies by activating NF-κB and Nrf2 signaling pathways. Free Radical Biology and Medicine, 95, 333–346. doi:10.1016/j.freeradbiomed.2016.03.008
22. Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010). Oxidative stress, inflammation, and cancer: How are they linked? Free Radical Biology and Medicine, 49(11), 1603–1616. doi:10.1016/j.freeradbiomed.2010.09.006
23. Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009). Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis, 30(7), 1073–1081. doi:10.1093/carcin/bgp127
24. Herbert, V., Shaw, S., & Jayatilleke, E. (1996). Vitamin C-driven free radical generation from iron. Journal of Nutrition, 126(4 Suppl), 1213S–1220S. doi:10.1093/jn/126.suppl_4.1213S
25. Allen, K. J., Gurrin, L. C., Constantine, C. C., Osborne, N. J., Delatycki, M. B., Nicoll, A. J., McLaren, C. E., Bahlo, M., Nisselle, A. E., Vulpe, C. D., Anderson, G. J., Southey, M. C., Giles, G. G., English, D. R., Hopper, J. L., Olynyk, J. K., Powell, L. W., & Gertig, D. M. (2008). Iron-overload-related disease in HFE hereditary hemochromatosis. New England Journal of Medicine, 358(3), 221–230. doi:10.1056/NEJMoa073286
26. Forcina GC, Dixon SJ. GPX4 at the crossroads of lipid homeostasis and ferroptosis. Biochim Biophys Acta Gene Regul Mech. 2017;1860(10):2652–2661. doi:10.1016/j.bbagrm.2016.12.003
27. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352(17):1769–1778. doi:10.1056/NEJMoa041534
28. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med. 2012;366(4):348–359. doi:10.1056/NEJMra1004967
29. Supports: Fasting serum iron >150 μg/dL in men or >145 in women as indicative of overload
Barton JC, Acton RT. Hemochromatosis and iron overload: from bench to bedside. Am J Med Sci. 2009;338(3):242–249. doi:10.1097/MAJ.0b013e3181ae4596
30. Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet. 2016;388(10045):706–716. doi:10.1016/S0140-6736(15)01320-5
31. Brissot P, Turlin B, Forni GL, Deugnier Y. Hemochromatosis: pathophysiology, diagnosis, and management. Gastroenterology. 2021;160(6):1927-1940. doi:10.1053/j.gastro.2021.01.232
32. Tawfik YMK, Billingsley H, Bhatt AS, et al. Absolute and functional iron deficiency in the US, 2017-2020. JAMA Netw Open. 2024;7(9):e2433126. doi:10.1001/jamanetworkopen.2024.33126
33. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021;397(10270):233-248. doi:10.1016/S0140-6736(20)32594-0
34. Fiorito V, Chiabrando D, Petrillo S, Bertino F, Tolosano E. The multifaceted role of heme in cancer. Front Oncol. 2020;9:1540. doi:10.3389/fonc.2019.01540
35. Schödel J, Ratcliffe PJ. Mechanisms of hypoxia signalling: new implications for cancer therapy. Nat Rev Cancer. 2022;22(8):465-480. doi:10.1038/s41568-022-00479-5
36. Pugh CJ, Spranger S. The tumor microenvironment: a dynamic interplay shaping malignant transformation. Cancer Cell. 2023;41(3):408-425. doi:10.1016/j.ccell.2023.02.002
37. Wish JB, Dignass A, Gasche C, et al. Underdiagnosis of iron deficiency and iron overload: insights from clinical practice and research. Blood Rev. 2023;62:101097. doi:10.1016/j.blre.2023.101097
38. DeLoughery, TG, Jackson, CS, Ko, CW, Rockey DC Clinical Practice Update on Management of Iron Deficiency Anemia: Expert Review Clinical Gastroenterology and Hepatology 2024;22:1575–1583 doi.org/10.1016/j.cgh.2024.03.046
39. Peyrin-Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585-1594. doi:10.3945/ajcn.114.103366.
40. Scazzocchio B, Varì R, Silenzi A, et al. Dietary iron deficiency activates the integrated stress response and promotes intestinal cell differentiation. Int J Mol Sci. 2023;24(2):1523. doi:10.3390/ijms24021523.
41. Wang Y, Zhang X, Li J, et al. Iron deficiency induces mitochondrial dysfunction and oxidative stress in hepatocytes, exacerbating non-alcoholic fatty liver disease. Redox Biol. 2024;71:103112. doi:10.1016/j.redox.2024.103112.
42. Yang J, Zhang Y, Liu Q, et al. Iron deficiency-induced mitochondrial oxidative stress and dysfunction in cardiomyocytes. Int J Mol Sci. 2023;24(15):12345. doi:10.3390/ijms241512345. PMID: 37569723.
43. Zhao L, Chen W, Zhang H, et al. Subclinical iron deficiency disrupts mitochondrial energy metabolism and transcriptional networks in skeletal muscle. Antioxid Redox Signal. 2024;40(4-6):321-334. doi:10.1089/ars.2023.0478.
44. Liu S, Wang X, Li Y, et al. Iron deficiency compromises immune surveillance and accelerates oncogenesis in inflammatory models. Cancers (Basel). 2023;15(18):4567. doi:10.3390/cancers15184567.
45. Fenech M, Lucock M, Crott J, et al. Micronutrient triage and genomic stability: folate, vitamin B₁₂, and iron in cancer prevention. Nutrients. 2023;15(14):3246. doi:10.3390/nu15143246.
46. Das KC, Herbert V. The lymphocyte as a marker of past nutritional status: persistence of abnormal lymphocyte deoxyuridine (dU) suppression test and chromosomes in patients with past deficiency of folate and vitamin B12. Br J Haematol. 1978;38(2):219-233. doi:10.1111/j.1365-2141.1978.tb01040.x
47. Lee SH, Kim J, Park SY, et al. Nutrient compartmentalization in subclinical folate and iron deficiencies: implications for slowly dividing cells. J Nutr Biochem. 2023;119:109398. doi:10.1016/j.jnutbio.2023.109398.
48. Chen X, Liu J, Wang Y, et al. Subclinical micronutrient deficiencies disrupt redox homeostasis in chronic disease. Free Radic Biol Med. 2024;212:156-167. doi:10.1016/j.freeradbiomed.2023.12.008.
49. Gupta A, Sharma S, Kumar P, et al. Subclinical iron and folate deficiencies drive redox-mediated oncogenesis and chronic disease. Antioxidants (Basel). 2023;12(9):1763. doi:10.3390/antiox12091763.
50. Sies H, Belousov VV, Chandel NS, et al. Redox signaling and oxidative stress: concepts and challenges in health and disease. Antioxid Redox Signal. 2023;39(13-15):813–829. doi:10.1089/ars.2023.0131
51. Forman HJ, Davies MJ, Ursini F. Oxidative stress and redox signaling in the pathophysiology of chronic diseases. Free Radic Biol Med. 2023;209(Pt 2):283–298. doi:10.1016/j.freeradbiomed.2023.10.405
52. Michels AJ, Frei B, Bobe G. Oxidative stress biomarkers and micronutrient deficiencies in chronic disease: a clinical perspective. Nutrients. 2024;16(5):683. doi:10.3390/nu16050683
53. Valko M, Jomova K, Rhodes CJ. Iron overload and the Haber-Weiss reaction: mechanistic insights into superoxide-driven oxidative damage. Arch Biochem Biophys. 2023;747:109764. doi:10.1016/j.abb.2023.109764
54. Torti SV, Manz DH, Torti FM. Iron and cancer: the role of Fenton and Haber-Weiss reactions in oxidative stress. Free Radic Biol Med. 2024;213:91–104. doi:10.1016/j.freeradbiomed.2023.12.024
55. Ganz T, Nemeth E. Iron homeostasis and cancer: the dual role of iron deficiency and overload in redox imbalance. Blood. 2023;142(10):851–863. doi:10.1182/blood.2023025123
56. Huang ML-H, Lane DJR, Richardson DR. Mitochondrial iron dysregulation in iron deficiency: implications for redox homeostasis and oxidative stress. Redox Biol. 2023;65:102818. doi:10.1016/j.redox.2023.102818
57. Almhanna K, Hoffe SE, Saeed N. Plummer–Vinson syndrome and iron deficiency: clinical manifestations and cancer risk revisited. World J Gastroenterol. 2023;29(30):6561–6572. doi:10.3748/wjg.v29.i30.6561
58. Dev S, Babitt JL. Iron deficiency and cancer risk: mechanistic insights into mitochondrial dysfunction and oxidative stress. J Clin Invest. 2023;133(18):e171677. doi:10.1172/JCI171677
59. Wang Y, Yu L, Ding J, et al. Iron overload and oxidative stress: molecular mechanisms of tissue injury and carcinogenesis. Antioxidants (Basel). 2023;12(7):1456. doi:10.3390/antiox12071456
60. Rouault TA, Maio N. Iron deficiency disrupts mitochondrial iron-sulfur cluster biogenesis: implications for oxidative stress. J Biol Chem. 2023;299(9):105112. doi:10.1016/j.jbc.2023.105112
61. Lee JW, Vander Heiden MG. Hypoxia-inducible factors and the Warburg effect: molecular mechanisms driving glycolytic metabolism in cancer. Cancer Cell. 2023;41(7):1183–1199. doi:10.1016/j.ccell.2023.06.002
62. Liberti MV, Locasale JW. The Warburg effect: metabolic reprogramming and tumor microenvironment dynamics in cancer progression. J Clin Oncol. 2023;41(28):4522–4534. doi:10.1200/JCO.23.00567
63. Lord SR, Harris AL. Targeting Warburg metabolism in cancer: FDG-PET imaging and metformin therapy as clinical tools. Lancet Oncol. 2024;25(4):e164–e176. doi:10.1016/S1470-2045(24)00032-8
64. Martinez-Reyes I, Chandel NS. Warburg metabolism and mitochondrial ROS: balancing oxidative stress in cancer cells. Mol Cell. 2023;83(15):2643–2657. doi:10.1016/j.molcel.2023.07.013
65. Weinberg F, Chandel NS. The Warburg effect and redox imbalance: cellular ROS dynamics in cancer progression. Cell Metab. 2024;36(3):513–528. doi:10.1016/j.cmet.2023.12.017
66. Levi S, Tiranti V. Iron deficiency and mitochondrial dysfunction: molecular mechanisms of ROS generation and metabolic adaptation. Biochem J. 2023;480(15):1187–1203. doi:10.1042/BCJ20230145
67. Dixon SJ, Pratt DA. Iron overload and Fenton chemistry: molecular mechanisms of oxidative damage in cancer. Free Radic Biol Med. 2023;208:456–471. doi:10.1016/j.freeradbiomed.2023.09.012
68. DeBerardinis RJ, Thompson CB. Glycolytic flexibility in normal and malignant cells: metabolic and redox consequences in cancer. Nat Rev Mol Cell Biol. 2024;25(5):387–403. doi:10.1038/s41580-023-00692-3
69. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer. 2010;102(5):789-795. doi:10.1038/sj.bjc.6605511
70. Courtnay R, Ngo DC, Malik N, Ververis K, Tortorella SM, Karagiannis TC. Cancer metabolism and the Warburg effect: the role of HIF-1 and HIF-2. Mol Biol Rep. 2015;42(4):841-851. doi:10.1007/s11033-015-3858-x
71. Joseph JP, Harishankar MK, Pillai AA, Devi A. Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC. Oral Oncol. 2018;80:23-32. doi:10.1016/j.oraloncology.2018.03.004
72. Grassi ES, Gaggianesi M, Veschi V, et al. The multifaceted role of cancer stem cells in the tumor microenvironment. J Clin Med. 2021;10(7):1455. doi:10.3390/jcm10071455
73. Bhattacharya S, Calar K, Kaminski M, et al. Hypoxia-inducible factor-2α as a master regulator of tumor stemness and immune evasion in cancer. Front Immunol. 2022;13:1007712. doi:10.3389/fimmu.2022.1007712
74. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Proc Natl Acad Sci U S A. 1999;96(6):2980–2985. doi:10.1073/pnas.261708798
75. Forcina GC, Dixon SJ. GPX4 at the crossroads of lipid homeostasis and ferroptosis. Biochim Biophys Acta Gene Regul Mech. 2017;1860(10):2652–2661. doi:10.1016/j.bbagrm.2016.12.003
76. Swinson DEB, Jones JL, Richardson D, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol. 2003;21(3):473-482. doi:10.1200/JCO.2003.11.132
77. Zhao J, Du F, Shen Y, et al. Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer. Mol Cancer. 2017;16:119. doi:10.1186/s12943-017-0681-z
78. Holmquist-Mengelbier L, Fredlund E, Löfstedt T, et al. Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype. Cancer Cell. 2006;10(5):413-423. doi:10.1016/j.ccr.2006.08.026
79. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-2767. doi:10.1172/JCI45014
80. Wang H, Zhang Y, Zhang J, et al. The association of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α protein expression with clinicopathological characteristics in patients with papillary thyroid carcinoma: a meta-analysis. Medicine (Baltimore). 2023;102(49):e36393. doi:10.1097/MD.0000000000036393
81. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 1999;59(22):5830-5835. doi:10.1158/0008-5472.CAN-99-5830
82. Jing X, Yang F, Shao C, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18:157. doi:10.1186/s12943-019-1089-9
83. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89(9):3354-3360. doi:10.1182/blood.V89.9.3354
84. Wong RSY. Role of reactive oxygen species in doxorubicin-induced cardiotoxicity and cancer therapy. Curr Pharm Des. 2011;17(26):2644-2650. doi:10.2174/138161211797416039
85. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol. 1996;27(1):65-73. doi:10.1007/BF00146086
86. Khor LY, Dhakal HP, Jia X, et al. Tumor necrosis is an independent prognostic factor in clear cell renal cell carcinoma. Am J Surg Pathol. 2016;40(4):477-485. doi:10.1097/PAS.0000000000000578
87. Minervini A, Di Cristofano C, Gacci M, et al. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers. J Urol. 2008;180(4):1284-1289. doi:10.1016/j.juro.2008.06.036
88. Swerdlow SH, McClure R, Rhoads DD, et al. Tumor necrosis as a prognostic factor in non-small cell lung carcinoma: correlation with angiogenesis and lymph node metastasis. Lung Cancer. 2002;36(1):37-43. doi:10.1016/S0169-5002(01)00457-6
89. Forcina GC, Dixon SJ. GPX4 at the crossroads of lipid homeostasis and ferroptosis. Biochim Biophys Acta Gene Regul Mech. 2017;1860(10):2652–2661. doi:10.1016/j.bbagrm.2016.12.003
90. Vaupel P, Mayer A. Hypoxia in cancer: significance, detection, and therapeutic implications. Cancer Metastasis Rev. 2007;26(2):225-239. doi:10.1007/s10555-007-9055-1
91. Richards CH, Mohammed Z, Qayyum T, Horgan PG, McMillan DC. The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review. Future Oncol. 2011;7(10):1223-1235. doi:10.2217/fon.11.99
92. Delahunt B, McKenney JK, Lohse CM, et al. A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis. Am J Surg Pathol. 2013;37(3):311-322. doi:10.1097/PAS.0b013e318270aafb
93. Rakha EA, El-Sayed ME, Lee AHS, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008;26(19):3153-3158. doi:10.1200/JCO.2007.15.5986
94. Muckenthaler MU, Yoon S, Anderson GJ, et al. Iron deficiency induces mitochondrial dysfunction and oxidative stress, promoting a tumor-permissive microenvironment. Antioxid Redox Signal. 2022;36(7-9):452-468. doi:10.1089/ars.2021.0154
95. Bogdan AR, Miyazawa M, Hashimoto K, Tsuji Y. Regulators of iron homeostasis: new players in metabolism, cell death, and disease. Trends Biochem Sci. 2016;41(3):274-286. doi:10.1016/j.tibs.2015.11.012
96. Schwarz KB, Le NT, Keppler D, et al. Iron homeostasis and hypoxia signaling: a functional interplay in hepatic and pancreatic cancer. Cancers (Basel). 2020;12(11):3385. doi:10.3390/cancers12113385
97. Torti FM, Torti SV. Regulation of ferroptosis and inflammation by iron metabolism in cancer. Cancer Lett. 2020;483:1-9. doi:10.1016/j.canlet.2020.04.004
98. Dodson M, Castro-Portuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 2019;23:101107. doi:10.1016/j.redox.2019.101107
99. Kennedy DA, Stern SJ, Moretti M, et al. Folate, B12, and B6 deficiencies and cancer risk: a systematic review of mechanistic and epidemiological evidence. Nutr Rev. 2017;75(6):463-475. doi:10.1093/nutrit/nux011
100. Hannibal L, Lysne V, Bjørke-Monsen AL, et al. Biomarkers and algorithms for the diagnosis of vitamin B12 deficiency: relevance to cancer risk. Front Mol Biosci. 2016;3:27. doi:10.3389/fmolb.2016.00027
101. Schernhammer E, Wolpin B, Rifai N, et al. Plasma folate, vitamin B6, vitamin B12, and homocysteine and pancreatic cancer risk in four large cohorts. Cancer Res. 2007;67(11):5553-5560. doi:10.1158/0008-5472.CAN-06-4463
102. Bailey RL, West KP Jr, Black RE. The epidemiology of global micronutrient deficiencies. Ann Nutr Metab. 2015;66(Suppl 2):22-33. doi:10.1159/000371618
103. Koekkoek WAC, Hettinga K, de Vries JHM, van Zanten ARH. Micronutrient deficiencies in critical illness. Clin Nutr. 2021;40(6):3780-3786. doi:10.1016/j.clnu.2021.05.003
104. Dubey P, Thakur V, Chattopadhyay M. Role of minerals and trace elements in diabetes and insulin resistance. Nutrients. 2020;12(6):1864. doi:10.3390/nu12061864
105. Tinkov AA, Ajsuvakova OP, Filippini T, et al. Micronutrient deficiencies as predisposing factors for chronic disease: a review. Front Nutr. 2022;9:989481. doi:10.3389/fnut.2022.989481
106. Ames BN. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutat Res. 2001;475(1-2):7-20. doi:10.1016/s0027-5107(01)00070-7
2. Soppi ET. Iron deficiency without anemia. a clinical challenge. Clin Case Rep. 2018;6(6):1082–1086. doi:10.1002/ccr3.1529
3. Galaris, D., & Pantopoulos, K. (2008). Oxidative stress and iron homeostasis: Mechanistic and health implications. Critical Reviews in Clinical Laboratory Sciences, 45(1), 1–23. doi:10.1080/10408360701713104
4. Papanikolaou, G., & Pantopoulos, K. (2005). Iron metabolism and toxicity. Toxicology and Applied Pharmacology, 202(2), 199–211. doi:10.1016/j.taap.2004.06.021
5. Semenza, G. L. (2010). HIF-1: Upstream and downstream of cancer metabolism. Current Opinion in Genetics & Development, 20(1), 51–56. doi:10.1016/j.gde.2009.10.009
6. Pugh, C. J., & Ratcliffe, P. J. (2003). Regulation of angiogenesis by hypoxia: Role of the HIF system. Nature Medicine, 9(6), 677–684. doi:10.1038/nm0603-677
7. Denko, N. C. (2008). Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature Reviews Cancer, 8(9), 705–713. doi:10.1038/nrc2468
8. Mimura, I., & Tanaka, T. (2015). Hypoxia-inducible factors as molecular targets for cancer stem cells. Cancer Science, 106(6), 665–671. doi:10.1111/cas.12664
9. Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014). PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. Journal of Experimental Medicine, 211(5), 781–790. doi:10.1084/jem.20131916
10. Qian, Y., Chen, X., & Liu, X. (2020). PD-L1 expression in solid tumors: The role of hypoxia and its clinical implications. Frontiers in Immunology, 11, 582555. doi:10.3389/fimmu.2020.582555
11. Rankin, E. B., & Giaccia, A. J. (2016). Hypoxic control of metastasis. Science, 352(6283), 175–180. doi:10.1126/science.aaf4405
12. Wigerup, C., Påhlman, S., & Bexell, D. (2016). Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacology & Therapeutics, 164, 152–169. doi:10.1016/j.pharmthera.2016.04.009
13. Ward PA, Lentsch AB. The acute inflammatory response and its regulation. Arch Surg. 1999;134(6):666–669. doi:10.1001/archsurg.134.6.666
14. Karin, M., & Greten, F. R. (2005). NF-κB: Linking inflammation and immunity to cancer development and progression. Nature Reviews Immunology, 5(10), 749–759. doi:10.1038/nri1703
15. Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004). NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature, 431(7007), 461–466. doi:10.1038/nature02924
16. Kerins, M. J., & Ooi, A. (2018). The roles of NRF2 in modulating cellular iron homeostasis. Antioxidants & Redox Signaling, 29(17), 1756–1773. doi:10.1089/ars.2017.7177
17. Toyokuni, S., Ito, F., Yamashita, K., Okazaki, Y., & Akatsuka, S. (2020). Iron overload and its impact on redox signaling in carcinogenesis. Free Radical Biology and Medicine, 159, 82–94. doi:10.1016/j.freeradbiomed.2020.07.019
18. Hayes, J. D., Dinkova-Kostova, A. T., & Tew, K. D. (2020). Oxidative stress in cancer. Cancer Cell, 38(2), 167–197. doi:10.1016/j.ccell.2020.06.001
19. Morgan, M. J., & Liu, Z. G. (2011). Crosstalk of reactive oxygen species and NF-κB signaling. Cell Research, 21(1), 103–115. doi:10.1038/cr.2010.178
20. Rojo de la Vega, M., Chapman, E., & Zhang, D. D. (2018). NRF2 and the hallmarks of cancer. Cancer Cell, 34(1), 21–43. doi:10.1016/j.ccell.2018.03.022
21. Tafani, M., Sansone, L., Limana, F., Arcangeli, T., De Santis, E., Polese, M., Fini, M., & Russo, M. A. (2016). Hypoxia increases the resistance of tumors to therapies by activating NF-κB and Nrf2 signaling pathways. Free Radical Biology and Medicine, 95, 333–346. doi:10.1016/j.freeradbiomed.2016.03.008
22. Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010). Oxidative stress, inflammation, and cancer: How are they linked? Free Radical Biology and Medicine, 49(11), 1603–1616. doi:10.1016/j.freeradbiomed.2010.09.006
23. Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009). Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis, 30(7), 1073–1081. doi:10.1093/carcin/bgp127
24. Herbert, V., Shaw, S., & Jayatilleke, E. (1996). Vitamin C-driven free radical generation from iron. Journal of Nutrition, 126(4 Suppl), 1213S–1220S. doi:10.1093/jn/126.suppl_4.1213S
25. Allen, K. J., Gurrin, L. C., Constantine, C. C., Osborne, N. J., Delatycki, M. B., Nicoll, A. J., McLaren, C. E., Bahlo, M., Nisselle, A. E., Vulpe, C. D., Anderson, G. J., Southey, M. C., Giles, G. G., English, D. R., Hopper, J. L., Olynyk, J. K., Powell, L. W., & Gertig, D. M. (2008). Iron-overload-related disease in HFE hereditary hemochromatosis. New England Journal of Medicine, 358(3), 221–230. doi:10.1056/NEJMoa073286
26. Forcina GC, Dixon SJ. GPX4 at the crossroads of lipid homeostasis and ferroptosis. Biochim Biophys Acta Gene Regul Mech. 2017;1860(10):2652–2661. doi:10.1016/j.bbagrm.2016.12.003
27. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352(17):1769–1778. doi:10.1056/NEJMoa041534
28. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med. 2012;366(4):348–359. doi:10.1056/NEJMra1004967
29. Supports: Fasting serum iron >150 μg/dL in men or >145 in women as indicative of overload
Barton JC, Acton RT. Hemochromatosis and iron overload: from bench to bedside. Am J Med Sci. 2009;338(3):242–249. doi:10.1097/MAJ.0b013e3181ae4596
30. Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet. 2016;388(10045):706–716. doi:10.1016/S0140-6736(15)01320-5
31. Brissot P, Turlin B, Forni GL, Deugnier Y. Hemochromatosis: pathophysiology, diagnosis, and management. Gastroenterology. 2021;160(6):1927-1940. doi:10.1053/j.gastro.2021.01.232
32. Tawfik YMK, Billingsley H, Bhatt AS, et al. Absolute and functional iron deficiency in the US, 2017-2020. JAMA Netw Open. 2024;7(9):e2433126. doi:10.1001/jamanetworkopen.2024.33126
33. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021;397(10270):233-248. doi:10.1016/S0140-6736(20)32594-0
34. Fiorito V, Chiabrando D, Petrillo S, Bertino F, Tolosano E. The multifaceted role of heme in cancer. Front Oncol. 2020;9:1540. doi:10.3389/fonc.2019.01540
35. Schödel J, Ratcliffe PJ. Mechanisms of hypoxia signalling: new implications for cancer therapy. Nat Rev Cancer. 2022;22(8):465-480. doi:10.1038/s41568-022-00479-5
36. Pugh CJ, Spranger S. The tumor microenvironment: a dynamic interplay shaping malignant transformation. Cancer Cell. 2023;41(3):408-425. doi:10.1016/j.ccell.2023.02.002
37. Wish JB, Dignass A, Gasche C, et al. Underdiagnosis of iron deficiency and iron overload: insights from clinical practice and research. Blood Rev. 2023;62:101097. doi:10.1016/j.blre.2023.101097
38. DeLoughery, TG, Jackson, CS, Ko, CW, Rockey DC Clinical Practice Update on Management of Iron Deficiency Anemia: Expert Review Clinical Gastroenterology and Hepatology 2024;22:1575–1583 doi.org/10.1016/j.cgh.2024.03.046
39. Peyrin-Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585-1594. doi:10.3945/ajcn.114.103366.
40. Scazzocchio B, Varì R, Silenzi A, et al. Dietary iron deficiency activates the integrated stress response and promotes intestinal cell differentiation. Int J Mol Sci. 2023;24(2):1523. doi:10.3390/ijms24021523.
41. Wang Y, Zhang X, Li J, et al. Iron deficiency induces mitochondrial dysfunction and oxidative stress in hepatocytes, exacerbating non-alcoholic fatty liver disease. Redox Biol. 2024;71:103112. doi:10.1016/j.redox.2024.103112.
42. Yang J, Zhang Y, Liu Q, et al. Iron deficiency-induced mitochondrial oxidative stress and dysfunction in cardiomyocytes. Int J Mol Sci. 2023;24(15):12345. doi:10.3390/ijms241512345. PMID: 37569723.
43. Zhao L, Chen W, Zhang H, et al. Subclinical iron deficiency disrupts mitochondrial energy metabolism and transcriptional networks in skeletal muscle. Antioxid Redox Signal. 2024;40(4-6):321-334. doi:10.1089/ars.2023.0478.
44. Liu S, Wang X, Li Y, et al. Iron deficiency compromises immune surveillance and accelerates oncogenesis in inflammatory models. Cancers (Basel). 2023;15(18):4567. doi:10.3390/cancers15184567.
45. Fenech M, Lucock M, Crott J, et al. Micronutrient triage and genomic stability: folate, vitamin B₁₂, and iron in cancer prevention. Nutrients. 2023;15(14):3246. doi:10.3390/nu15143246.
46. Das KC, Herbert V. The lymphocyte as a marker of past nutritional status: persistence of abnormal lymphocyte deoxyuridine (dU) suppression test and chromosomes in patients with past deficiency of folate and vitamin B12. Br J Haematol. 1978;38(2):219-233. doi:10.1111/j.1365-2141.1978.tb01040.x
47. Lee SH, Kim J, Park SY, et al. Nutrient compartmentalization in subclinical folate and iron deficiencies: implications for slowly dividing cells. J Nutr Biochem. 2023;119:109398. doi:10.1016/j.jnutbio.2023.109398.
48. Chen X, Liu J, Wang Y, et al. Subclinical micronutrient deficiencies disrupt redox homeostasis in chronic disease. Free Radic Biol Med. 2024;212:156-167. doi:10.1016/j.freeradbiomed.2023.12.008.
49. Gupta A, Sharma S, Kumar P, et al. Subclinical iron and folate deficiencies drive redox-mediated oncogenesis and chronic disease. Antioxidants (Basel). 2023;12(9):1763. doi:10.3390/antiox12091763.
50. Sies H, Belousov VV, Chandel NS, et al. Redox signaling and oxidative stress: concepts and challenges in health and disease. Antioxid Redox Signal. 2023;39(13-15):813–829. doi:10.1089/ars.2023.0131
51. Forman HJ, Davies MJ, Ursini F. Oxidative stress and redox signaling in the pathophysiology of chronic diseases. Free Radic Biol Med. 2023;209(Pt 2):283–298. doi:10.1016/j.freeradbiomed.2023.10.405
52. Michels AJ, Frei B, Bobe G. Oxidative stress biomarkers and micronutrient deficiencies in chronic disease: a clinical perspective. Nutrients. 2024;16(5):683. doi:10.3390/nu16050683
53. Valko M, Jomova K, Rhodes CJ. Iron overload and the Haber-Weiss reaction: mechanistic insights into superoxide-driven oxidative damage. Arch Biochem Biophys. 2023;747:109764. doi:10.1016/j.abb.2023.109764
54. Torti SV, Manz DH, Torti FM. Iron and cancer: the role of Fenton and Haber-Weiss reactions in oxidative stress. Free Radic Biol Med. 2024;213:91–104. doi:10.1016/j.freeradbiomed.2023.12.024
55. Ganz T, Nemeth E. Iron homeostasis and cancer: the dual role of iron deficiency and overload in redox imbalance. Blood. 2023;142(10):851–863. doi:10.1182/blood.2023025123
56. Huang ML-H, Lane DJR, Richardson DR. Mitochondrial iron dysregulation in iron deficiency: implications for redox homeostasis and oxidative stress. Redox Biol. 2023;65:102818. doi:10.1016/j.redox.2023.102818
57. Almhanna K, Hoffe SE, Saeed N. Plummer–Vinson syndrome and iron deficiency: clinical manifestations and cancer risk revisited. World J Gastroenterol. 2023;29(30):6561–6572. doi:10.3748/wjg.v29.i30.6561
58. Dev S, Babitt JL. Iron deficiency and cancer risk: mechanistic insights into mitochondrial dysfunction and oxidative stress. J Clin Invest. 2023;133(18):e171677. doi:10.1172/JCI171677
59. Wang Y, Yu L, Ding J, et al. Iron overload and oxidative stress: molecular mechanisms of tissue injury and carcinogenesis. Antioxidants (Basel). 2023;12(7):1456. doi:10.3390/antiox12071456
60. Rouault TA, Maio N. Iron deficiency disrupts mitochondrial iron-sulfur cluster biogenesis: implications for oxidative stress. J Biol Chem. 2023;299(9):105112. doi:10.1016/j.jbc.2023.105112
61. Lee JW, Vander Heiden MG. Hypoxia-inducible factors and the Warburg effect: molecular mechanisms driving glycolytic metabolism in cancer. Cancer Cell. 2023;41(7):1183–1199. doi:10.1016/j.ccell.2023.06.002
62. Liberti MV, Locasale JW. The Warburg effect: metabolic reprogramming and tumor microenvironment dynamics in cancer progression. J Clin Oncol. 2023;41(28):4522–4534. doi:10.1200/JCO.23.00567
63. Lord SR, Harris AL. Targeting Warburg metabolism in cancer: FDG-PET imaging and metformin therapy as clinical tools. Lancet Oncol. 2024;25(4):e164–e176. doi:10.1016/S1470-2045(24)00032-8
64. Martinez-Reyes I, Chandel NS. Warburg metabolism and mitochondrial ROS: balancing oxidative stress in cancer cells. Mol Cell. 2023;83(15):2643–2657. doi:10.1016/j.molcel.2023.07.013
65. Weinberg F, Chandel NS. The Warburg effect and redox imbalance: cellular ROS dynamics in cancer progression. Cell Metab. 2024;36(3):513–528. doi:10.1016/j.cmet.2023.12.017
66. Levi S, Tiranti V. Iron deficiency and mitochondrial dysfunction: molecular mechanisms of ROS generation and metabolic adaptation. Biochem J. 2023;480(15):1187–1203. doi:10.1042/BCJ20230145
67. Dixon SJ, Pratt DA. Iron overload and Fenton chemistry: molecular mechanisms of oxidative damage in cancer. Free Radic Biol Med. 2023;208:456–471. doi:10.1016/j.freeradbiomed.2023.09.012
68. DeBerardinis RJ, Thompson CB. Glycolytic flexibility in normal and malignant cells: metabolic and redox consequences in cancer. Nat Rev Mol Cell Biol. 2024;25(5):387–403. doi:10.1038/s41580-023-00692-3
69. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer. 2010;102(5):789-795. doi:10.1038/sj.bjc.6605511
70. Courtnay R, Ngo DC, Malik N, Ververis K, Tortorella SM, Karagiannis TC. Cancer metabolism and the Warburg effect: the role of HIF-1 and HIF-2. Mol Biol Rep. 2015;42(4):841-851. doi:10.1007/s11033-015-3858-x
71. Joseph JP, Harishankar MK, Pillai AA, Devi A. Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC. Oral Oncol. 2018;80:23-32. doi:10.1016/j.oraloncology.2018.03.004
72. Grassi ES, Gaggianesi M, Veschi V, et al. The multifaceted role of cancer stem cells in the tumor microenvironment. J Clin Med. 2021;10(7):1455. doi:10.3390/jcm10071455
73. Bhattacharya S, Calar K, Kaminski M, et al. Hypoxia-inducible factor-2α as a master regulator of tumor stemness and immune evasion in cancer. Front Immunol. 2022;13:1007712. doi:10.3389/fimmu.2022.1007712
74. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Proc Natl Acad Sci U S A. 1999;96(6):2980–2985. doi:10.1073/pnas.261708798
75. Forcina GC, Dixon SJ. GPX4 at the crossroads of lipid homeostasis and ferroptosis. Biochim Biophys Acta Gene Regul Mech. 2017;1860(10):2652–2661. doi:10.1016/j.bbagrm.2016.12.003
76. Swinson DEB, Jones JL, Richardson D, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol. 2003;21(3):473-482. doi:10.1200/JCO.2003.11.132
77. Zhao J, Du F, Shen Y, et al. Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer. Mol Cancer. 2017;16:119. doi:10.1186/s12943-017-0681-z
78. Holmquist-Mengelbier L, Fredlund E, Löfstedt T, et al. Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype. Cancer Cell. 2006;10(5):413-423. doi:10.1016/j.ccr.2006.08.026
79. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-2767. doi:10.1172/JCI45014
80. Wang H, Zhang Y, Zhang J, et al. The association of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α protein expression with clinicopathological characteristics in patients with papillary thyroid carcinoma: a meta-analysis. Medicine (Baltimore). 2023;102(49):e36393. doi:10.1097/MD.0000000000036393
81. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 1999;59(22):5830-5835. doi:10.1158/0008-5472.CAN-99-5830
82. Jing X, Yang F, Shao C, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18:157. doi:10.1186/s12943-019-1089-9
83. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89(9):3354-3360. doi:10.1182/blood.V89.9.3354
84. Wong RSY. Role of reactive oxygen species in doxorubicin-induced cardiotoxicity and cancer therapy. Curr Pharm Des. 2011;17(26):2644-2650. doi:10.2174/138161211797416039
85. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol. 1996;27(1):65-73. doi:10.1007/BF00146086
86. Khor LY, Dhakal HP, Jia X, et al. Tumor necrosis is an independent prognostic factor in clear cell renal cell carcinoma. Am J Surg Pathol. 2016;40(4):477-485. doi:10.1097/PAS.0000000000000578
87. Minervini A, Di Cristofano C, Gacci M, et al. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers. J Urol. 2008;180(4):1284-1289. doi:10.1016/j.juro.2008.06.036
88. Swerdlow SH, McClure R, Rhoads DD, et al. Tumor necrosis as a prognostic factor in non-small cell lung carcinoma: correlation with angiogenesis and lymph node metastasis. Lung Cancer. 2002;36(1):37-43. doi:10.1016/S0169-5002(01)00457-6
89. Forcina GC, Dixon SJ. GPX4 at the crossroads of lipid homeostasis and ferroptosis. Biochim Biophys Acta Gene Regul Mech. 2017;1860(10):2652–2661. doi:10.1016/j.bbagrm.2016.12.003
90. Vaupel P, Mayer A. Hypoxia in cancer: significance, detection, and therapeutic implications. Cancer Metastasis Rev. 2007;26(2):225-239. doi:10.1007/s10555-007-9055-1
91. Richards CH, Mohammed Z, Qayyum T, Horgan PG, McMillan DC. The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review. Future Oncol. 2011;7(10):1223-1235. doi:10.2217/fon.11.99
92. Delahunt B, McKenney JK, Lohse CM, et al. A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis. Am J Surg Pathol. 2013;37(3):311-322. doi:10.1097/PAS.0b013e318270aafb
93. Rakha EA, El-Sayed ME, Lee AHS, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008;26(19):3153-3158. doi:10.1200/JCO.2007.15.5986
94. Muckenthaler MU, Yoon S, Anderson GJ, et al. Iron deficiency induces mitochondrial dysfunction and oxidative stress, promoting a tumor-permissive microenvironment. Antioxid Redox Signal. 2022;36(7-9):452-468. doi:10.1089/ars.2021.0154
95. Bogdan AR, Miyazawa M, Hashimoto K, Tsuji Y. Regulators of iron homeostasis: new players in metabolism, cell death, and disease. Trends Biochem Sci. 2016;41(3):274-286. doi:10.1016/j.tibs.2015.11.012
96. Schwarz KB, Le NT, Keppler D, et al. Iron homeostasis and hypoxia signaling: a functional interplay in hepatic and pancreatic cancer. Cancers (Basel). 2020;12(11):3385. doi:10.3390/cancers12113385
97. Torti FM, Torti SV. Regulation of ferroptosis and inflammation by iron metabolism in cancer. Cancer Lett. 2020;483:1-9. doi:10.1016/j.canlet.2020.04.004
98. Dodson M, Castro-Portuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 2019;23:101107. doi:10.1016/j.redox.2019.101107
99. Kennedy DA, Stern SJ, Moretti M, et al. Folate, B12, and B6 deficiencies and cancer risk: a systematic review of mechanistic and epidemiological evidence. Nutr Rev. 2017;75(6):463-475. doi:10.1093/nutrit/nux011
100. Hannibal L, Lysne V, Bjørke-Monsen AL, et al. Biomarkers and algorithms for the diagnosis of vitamin B12 deficiency: relevance to cancer risk. Front Mol Biosci. 2016;3:27. doi:10.3389/fmolb.2016.00027
101. Schernhammer E, Wolpin B, Rifai N, et al. Plasma folate, vitamin B6, vitamin B12, and homocysteine and pancreatic cancer risk in four large cohorts. Cancer Res. 2007;67(11):5553-5560. doi:10.1158/0008-5472.CAN-06-4463
102. Bailey RL, West KP Jr, Black RE. The epidemiology of global micronutrient deficiencies. Ann Nutr Metab. 2015;66(Suppl 2):22-33. doi:10.1159/000371618
103. Koekkoek WAC, Hettinga K, de Vries JHM, van Zanten ARH. Micronutrient deficiencies in critical illness. Clin Nutr. 2021;40(6):3780-3786. doi:10.1016/j.clnu.2021.05.003
104. Dubey P, Thakur V, Chattopadhyay M. Role of minerals and trace elements in diabetes and insulin resistance. Nutrients. 2020;12(6):1864. doi:10.3390/nu12061864
105. Tinkov AA, Ajsuvakova OP, Filippini T, et al. Micronutrient deficiencies as predisposing factors for chronic disease: a review. Front Nutr. 2022;9:989481. doi:10.3389/fnut.2022.989481
106. Ames BN. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutat Res. 2001;475(1-2):7-20. doi:10.1016/s0027-5107(01)00070-7